Citrix NetScaler ADC and NetScaler Gateway customers have been hit by a new round of zero day vulnerabilities that require urgent patching, including one the company warned is being actively exploited ...

Explore how digital feedback controllers manage motors, pressure, temperature, and more, and learn why ADC and DAC performance are crucial when designing robust embedded systems. How to define the ...

Marine Products Corporation faces near-term headwinds from weak demand, inflation, and interest rates, making current fundamentals look fairly valued rather than cheap. Despite recent underperformance ...

Cyber security experts are urging operators of Citrix NetScaler Application Delivery Controller (ADC) and NetScaler Gateway appliances to get in front of a new vulnerability – quietly patched last ...

Citrix has fixed a critical vulnerability, tracked as CVE-2025-5777, found within NetScaler ADC and NetScaler Gateway. The vulnerability, assigned a critical CVSS score of 9.3, is described as an ...

While the race is on to develop antibody-drug conjugate (ADC) cancer treatments, so too is the competition to manufacture them. Hoping to gain an edge in the rapidly growing market are MilliporeSigma ...

Good morning, and thank you for joining us for the Marine Products Corporation’s First Quarter 2025 Earnings Conference Call. Today’s call will be hosted by Ben Palmer, President and CEO; and Mike ...

Forbes contributors publish independent expert analyses and insights. I track enterprise software application development & data management. Platforms dominate technology. We talk about Microsoft’s ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

Recent regulatory activities suggest that the understanding of TROP2-directed therapies remains muddled. TROP2-directed therapies, specifically antibody-drug conjugates (ADCs), have evolved in ...

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate (ADC), trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low ...